Publish in this journal
Journal Information
Vol. 55. Issue 8.
Pages 446-447 (August 2019)
Share
Share
Download PDF
More article options
Vol. 55. Issue 8.
Pages 446-447 (August 2019)
Scientific Letter
Full text access
Acute Respiratory Distress Syndrome Secondary to Histoplasmosis-induced Hemophagocytic Lymphohistiocytosis
Síndrome de distrés respiratorio agudo secundario a linfohistiocitosis hemofagocítica inducida por histoplasmosis
Visits
...
Julio Arturo Huapayaa,
Corresponding author
julioarturo30@gmail.com

Corresponding author.
, Elizabeth Yogiaveetilb, Syed Qamera, Mary Sidawyc, Eric Andersonb
a Division of Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, United States
b Division of Pulmonary and Critical Care Medicine, Medstar Georgetown University Hospital, Washington, DC, United States
c Department of Pathology, Medstar Georgetown University Hospital, Washington, DC, United States
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
Dear Editor:

Acute respiratory distress syndrome (ARDS) is a condition that carries high mortality and can be caused by sepsis or pneumonia.1 Histoplasmosis can cause a lung infection varying from mild pneumonitis to ARDS.2 This endemic mycosis can also cause disseminated infection and is catastrophic in immunocompromised patients.3 In transplant populations, it has an incidence of 1–3 cases per 1000 patients and is more prevalent in hepatic and renal transplants.4–6 Hemophagocytic lymphohistiocytosis (HLH) is characterized by immune derangement of defective natural killer cells and macrophage overactivation. HLH is a rare complication of histoplasmosis but carries a mortality of up to 50%. Optimal treatment of infection-associated HLH is controversial and data is limited.7,8 Some physicians advocate for the use immunosuppression in addition to antifungal therapy, whereas others will only treat the underlying infection. Notably, current evidence suggests that this latter approach has less mortality.3,9–11

We present a case of a 46-year-old Korean male who underwent a deceased donor kidney transplant in 2014 secondary to diabetic nephropathy. He presented with vomiting, diarrhea and fever and was initially treated for viral gastroenteritis. Chest X-ray (CXR) on admission showed bibasilar linear infiltrates (Fig. 1A). His clinical status rapidly deteriorated and he was admitted to the intensive care unit and was started on low-dose vasopressors. Patient's hemodynamics continued to worsen with respiratory failure requiring high-flow nasal cannula due to hypoxemia. He rapidly developed ARDS and required intubation with low-tidal volume ventilation and paralytics. Chest X-ray revealed diffuse bilateral alveolar infiltrates with air bronchogram (Fig. 1B) and chest computed tomography revealed tree-in-bud infiltrates and splenomegaly. Laboratory data was notable for pancytopenia, transaminitis, ferritin of 16,624ng/mL, elevated LDH, normal triglycerides and a positive urine and serum Histoplasma antigen. He had several environmental and animal exposures including bats, rats, animal droppings and mold along subway tunnels. Work-up including acid-fast Bacilli smear and culture, hepatitis panel, Bartonella, Human Immunodeficiency Virus (HIV), Legionella, Cryptococcus, Parvovirus, Human Herpes Virus 6, Adenovirus, Epstein-barr Virus and Cytomegalovirus polymerase chain reaction tests were negative. Bronchoalveolar lavage revealed numerous fungal organisms in the form of budding yeasts without evidence of pseudohyphae, consistent with Histoplasma Capsulatum. Culture data confirmed the diagnosis. The patient rapidly improved and was successfully extubated after starting amphotericin B, followed by itraconazole. Soluble IL-2 receptor came back elevated (14,150pg/mL) a few days later. Tacrolimus and mofetil mycophenolate had been initially stopped due to worsening renal function but were restarted before discharge. The patient was fully recovered at 6-month follow up.

Fig. 1.

Chest X-ray on admission and at 12-h follow-up. (A) Bibasilar linear infiltrates seen on admission. (B) Diffuse bilateral alveolar infiltrates with air bronchogram seen 12h after admission.

(0.11MB).

This case highlights that patients with significant immunosuppression can develop severe ARDS secondary to histoplasmosis.2 This has mainly been described in patients with HIV who can also develop HLH as a rare complication.3 The current treatment of primary HLH is based on immunosuppression12 but there is not consensus on the treatment of infection-associated HLH.8 Moreover, the literature in organ transplants patients is limited. One study reported less mortality in patients who do not receive additional immunosuppression, although only a small number of patients were included in that study.3 Our patient met five criteria for HLH, including fever, splenomegaly, pancytopenia, high ferritin level and elevated IL2 soluble receptor. He had an excellent response to treatment targeting histoplasmosis without the use of steroids or further immunosuppression. In the largest case series of 11 cases of patients with histoplasmosis-induced HLH, the mortality was 46% at 30 days and 63% at 90 days, with increased mortality up to 80% in the group who received immunosuppression.3 The study included nine patients with HIV and two with renal transplants.3 Further evidence of HLH and histoplasmosis in kidney transplant is scarce. Nieto et al. report two cases, one successfully treated with antifungals alone and one with a fatal outcome after receiving increased immunosuppression.9 Similarly, Contreras et al. report a renal transplant patient who successfully responded to antifungal therapy alone.10 Lo et al. describe a successful experience of two kidney transplant patients who received only dual antifungal therapy with amphotericin and itraconazole.11 Notably, there were no acute rejections in spite of decreased immunosuppression. Therefore, it should be highlighted that limiting immunosuppression may be necessary if patients are refractory to antifungal therapy to ensure complete resolution of Histoplasmosis infection. In our patient, we held immunosuppression on admission and he did not experience any complications. Limitations related to the small number of patients and the possibility of treatment bias in patients who were sicker should be considered. Prospective treatment studies would be ideal, but they are unlikely given the rarity of this disease. In conclusion, our case adds to the limited literature that suggests that treatment of an underlying infection in HLH alone could lead to rapid resolution of this otherwise lethal disorder. Further data is needed to define the role of immunosuppression in treating this condition.

References
[1]
B.T. Thompson, R.C. Chambers, K.D. Liu.
Acute respiratory distress syndrome.
N. Engl. J. Med., 377 (2017), pp. 562-572
[2]
C.A. Kauffman.
Histoplasmosis:a clinical and laboratory update.
Clin. Microbiol. Rev., 20 (2007), pp. 115-132
[3]
J.L. Townsend, S. Shanbhag, J. Hancock, K. Bowman, A.E. Nijhawan.
Histoplasmosis-induced hemophagocytic syndrome: a case series and review of the literature.
Open Forum Infect Dis, 2 (2015),
[4]
J. Cuellar-Rodriguez, R.K. Avery, M. Lard, M. Budev, S.M. Gordon, N.K. Shrestha, et al.
Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area.
Clin. Infect. Dis., 49 (2009), pp. 710-716
[5]
A.G. Freifeld, L.J. Wheat, D.R. Kaul.
Histoplasmosis in solid organ transplant recipients: early diagnosis and treatment.
Curr Opin Organ Transplant, 14 (2009), pp. 601-605
[6]
K. Gajurel, R. Dhakal, S. Deresinski.
Diagnosis and treatment of histoplasmosis in solid organ transplant patients.
Curr Opin Infect Dis, 31 (2018), pp. 301-308
[7]
R.V. Untanu, S. Akbar, S. Graziano, N. Vajpayee.
Histoplasmosis-induced hemophagocytic lymphohistiocytosis in an adult patient: a case report and review of the literature.
Case Rep Infect Dis, 2016 (2016), pp. 5
[8]
A.M. Schram, N. Berliner.
How I treat hemophagocytic lymphohistiocytosis in the adult patient.
Blood, 125 (2015), pp. 2908-2914
[9]
J.F. Nieto-Rios, A. Aristizabal-Alzate, C. Ocampo, A.K. Serrano-Gayubo, L.M. Serna-Higuita, G. Zuluaga-Valencia.
Disseminated histoplasmosis and haemophagocytic syndrome in two kidney transplant patients.
[10]
K. Contreras, P. García, J. Pinto, P. Rodriguez, C. González, M.J.V. Brochero.
Histoplasmosis diseminada y síndrome hemofagocítico en trasplante renal.
Rev Colomb Nefrol, 4 (2017), pp. 93-98
[11]
M.M. Lo, J.Q. Mo, B.P. Dixon, K.A. Czech.
Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients.
Am. J. Transplant., 10 (2010), pp. 687-691
[12]
H. Trottestam, A.C. Horne, M. Aricò, R.M. Egeler, A.H. Filipovich, H. Gadner, et al.
Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol.
Blood, 118 (2011), pp. 4577-4584
Copyright © 2019. SEPAR
Archivos de Bronconeumología

Subscribe to our newsletter

Article options
Tools

Are you a health professional able to prescribe or dispense drugs?